l-alanyl-l-glutamine

Small moleculeexperimental

Clinical trial activity

14 trials · 16 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
8
Phase 3
5
Phase 4
4

Earliest trial started Jun 1, 2001 (NCT00558155)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • Unspecified targetSupplementation

    supplementation

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)O
Mol. weight
217.22 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ala-gln
  • alanylglutamine
  • alanylglutamine
  • alanylglutamine
  • alanyl glutamine
  • alanyl glutamine
  • alanyl glutamine
  • alanyl glutamine
  • alanyl glutamine
  • alanyl-glutamine
  • alanyl-glutamine
  • alanyl-glutamine
  • alanyl-glutamine
  • alanylglutamine, (d-glu)-isomer
  • dipeptamin
  • dipeptiven
  • dipeptiven
  • dipeptiven
  • l-ala-l-gln
  • l-alanyl-l-glutamine
  • n(2)-l-alanyl-l-glutamine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04560309Phase 3Oct 31, 2020University of Indonesia
NCT06065566N/AFeb 4, 2020Instituto Mexicano del Seguro Social
NCT04019184Phase 3Jul 31, 2019Fresenius, University of Munster
NCT02053350Phase 2Apr 1, 2015University of Virginia
NCT04250467Phase 1/Phase 2 (Phase 2)Feb 15, 2015Temple Therapeutics BV
NCT01832636Phase 3Oct 1, 2013Federal University of Ceara, University of Cincinnati
NCT01353638Phase 1/Phase 2 (Phase 2)Apr 1, 2011Medical University of Vienna, University of Vienna
NCT00647036Phase 4Jul 1, 2008National Institutes of Health (NIH)
NCT01704664N/AMar 1, 2007Medical University of Bialystok
NCT02130674Phase 4Jan 1, 2005Fresenius, Swiss National Science Foundation, University of Zurich
NCT00338221Phase 3Aug 1, 2004National Institute of Allergy and Infectious Diseases (NIAID), University of Virginia
NCT00133562Phase 3Aug 1, 2004National Institute of Allergy and Infectious Diseases (NIAID), University of Virginia
NCT00732849Phase 4Jun 1, 2002Jagiellonian University
NCT00558155Phase 4Jun 1, 2001Jagiellonian University
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of VirginiaAcademic/Hospital3322004
FreseniusFor profit2022005
Jagiellonian UniversityAcademic/Hospital2212001
National Institute of Allergy and Infectious Diseases (NIAID)Government2012004
Federal University of CearaAcademic/Hospital1012013
Instituto Mexicano del Seguro SocialGovernment1112020
Medical University of BialystokAcademic/Hospital1112007
Medical University of ViennaAcademic/Hospital1112011
National Institutes of Health (NIH)Government1112008
Swiss National Science FoundationGovernment1012005
Temple Therapeutics BVFor profit1112015
University of CincinnatiAcademic/Hospital1112013
University of IndonesiaAcademic/Hospital1112020
University of MunsterAcademic/Hospital1112019
University of ViennaAcademic/Hospital1012011
University of ZurichAcademic/Hospital1112005
16 organizations
Page 1 / 1